The primary endpoint was the functionality of the meibomian glands. The Korb Meibomian Bland Expressor was used to assess the meibomian gland function. The investigators determined the number of meibomian glands yielding liquid secretion at the four time points. Best-corrected visual acuity (BCVA) and adverse events were recorded.
A look at the results
Twenty-six patients (21 women, 5 men; 52 eyes) were included in the study, 13 in each of the two study groups. The mean patient age was 41.7 years (range, 18 to 72 years).
“The meibomian gland functionality was significantly better in the Systane group compared with the warm compresses groups at months 2 and 3,” Dr. Finnemore said.
At the baseline evaluation the mean numbers of meibomian glands yielding liquid secretion were similar in the two groups, i.e., 3.5 ± 1.50 in the Systane group and 4.2 ± 1.39 in the warm compresses group. In the Systane group, the mean numbers increased compared with baseline at all time points: 7.0, 6.4, and 9.3 at months 1, 2, and 3 compared with 3.9, 3.5, and 4.7 in the warm compresses group at the same time points. The differences were significant at months 2 and 3 (p = 0.365 and p = 0.0061, respectively).
The safety profile of the products was good and no serious adverse events were reported. One patient reported infectious mononucleosis and sinusitis that were not related to treatment. BCVA did not change during the study.
Dr. Finnemore also commented on the condition of the eyelids.